Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

Amivantamab (Rybrevant) with carboplatin and pemetrexed is available during the managed access period. It is a possible treatment for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.

More evidence on amivantamab with carboplatin and pemetrexed is being collected. After this, NICE will decide whether to recommend it for use on the NHS and update the guidance. It will be available during the managed access period until then.

If you are not eligible for amivantamab with carboplatin and pemetrexed but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on shared decision making.

Questions to think about

• How well does it work compared with other treatments?
• What are the risks or side effects? How likely are they?
• How will the treatment affect my day-to-day life?
• What happens if the treatment does not work?
• What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS webpage on lung cancer may be a good place to find out more.

These organisations can give you advice and support:

• EGFR Positive UK, contact@egfrpositive.org.uk
• Roy Castle Lung Cancer Foundation, 0333 323 7200
• Lung Cancer Nursing UK (LCNUK), 01675 477607
• Cancer Research UK, 0808 800 4040
• Macmillan Cancer Support, 0808 808 0000.

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9531-8